Medicaid Drug Rule Could Have 340B, Medicare Pay Implications

CMS proposes to loosen Medicaid rules to facilitate value-based contracts for drugs and could have implications for the 340B program, independent physicians' Medicare drug reimbursement, and patients' expenses. Debra Patt, M.D., Ph.D., MBA, medical oncologist and executive vice president at Texas Oncology, discusses concerns around patients stopping treatment courses due to manufacturers changing their copay coupon programs.

View the full story at Modern Healthcare.